Primary Immunodeficiency Diseases (PID) Clinical Trial
Official title:
Evaluation of Subcutaneous Immunoglobulin Product Cutaquig in Terms of Safety and Efficacy in the Treatment of Patients With Primary Immunodeficiencies
In the prospective part of the study, patients diagnosed with PID will receive replacement therapy with Cutaquig for at least 6 months and will be randomised with the help of physicians of the Russian PID Registry. At the beginning of the study, data on the prior intravenous immunoglobulin (IVIG) therapy efficacy will be extracted from patients' medical records (retrospective part of study). Also, at the beginning of the study, patients or their parents will be asked to complete Quality of Life Questionnaire for children, version 4.0; short form in Russian - Pediatric Quality of Life Inventory Russian, Version 4.0 (Russia), PedSQL (Appendix 14.1). During the 6 months of treatment with Cutaquig, investigators will enter information on infectious episodes, IgG levels (at least 3 times during the study period), and definition of an adverse drug reaction / serious adverse drug reaction, in the database. After 6 months, patients/their parents will be asked to complete the PedSQL, Quality of Life Questionnaire again. If the patient continues to receive the drug, and patient and his/her legally acceptable representatives (for patients under 14 years of age) agree to continue participating in the study, similar information will be collected for another 6 months. The first 6 months are planned for the main study period, 6-12 months for an extended study period. Data obtained in the prospective phase of the study will be compared with similar data obtained in the retrospective phase in the same patients
In the prospective part of the study, patients diagnosed with PID will receive replacement therapy with Cutaquig for at least 6 months and will be randomised with the help of physicians of the Russian PID Registry. At the beginning of the study, data on the prior intravenous immunoglobulin (IVIG) therapy efficacy will be extracted from patients' medical records (retrospective part of study). Also, at the beginning of the study, patients or their parents will be asked to complete Quality of Life Questionnaire for children, version 4.0; short form in Russian - Pediatric Quality of Life Inventory Russian, Version 4.0 (Russia), PedSQL (Appendix 14.1). During the 6 months of treatment with Cutaquig, investigators will enter information on infectious episodes, IgG levels (at least 3 times during the study period), and definition of an adverse drug reaction / serious adverse drug reaction, in the database. After 6 months, patients/their parents will be asked to complete the PedSQL, Quality of Life Questionnaire again. If the patient continues to receive the drug, and patient and his/her legally acceptable representatives (for patients under 14 years of age) agree to continue participating in the study, similar information will be collected for another 6 months. The first 6 months are planned for the main study period, 6-12 months for an extended study period. Data obtained in the prospective phase of the study will be compared with similar data obtained in the retrospective phase in the same patients. Considering the lack of the study drug marketing authorisation in the Russian Federation, study drug doses and treatment regimens were chosen as per current clinical practice and instructions for human use approved in other countries. Conventionally, on switching from IVIG therapy, the subcutaneous immunoglobulin products are administered at the same monthly dose (0.4-0.8 g/kg), evenly divided into 3-5 administrations per month, subject to monitoring of the pre transfusion IgG level with target IgG values of at least 7 g/L. All this information will be reflected in the Case record forms (CRF). Besides, information about therapeutic strategies, such as dose change or therapy change, will also be entered in the CRF. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03277313 -
Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects
|
Phase 3 | |
| Completed |
NCT03716700 -
Real-world CANadian CUvitru Non-Interventional Study in Subjects Transitioning From Subcutaneous Immunoglobulin (CANCUN)
|
||
| Active, not recruiting |
NCT05513586 -
A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants
|
Phase 3 | |
| Completed |
NCT00546871 -
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05755035 -
A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases
|
Phase 2/Phase 3 | |
| Completed |
NCT02593188 -
Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)
|
||
| Completed |
NCT03116347 -
Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD Subjects
|
Phase 4 | |
| Completed |
NCT00157079 -
Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders
|
Phase 3 | |
| Completed |
NCT01412385 -
Immune Globulin Subcutaenous (Human), 20%
|
Phase 2/Phase 3 | |
| Completed |
NCT00161993 -
Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia)
|
Phase 2 | |
| Completed |
NCT01175213 -
Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID
|
Phase 3 | |
| Completed |
NCT01218438 -
Phase 2/3 Study of IGSC, 20% in PIDD
|
Phase 2/Phase 3 | |
| Completed |
NCT05150340 -
A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (PID)
|
Phase 3 | |
| Not yet recruiting |
NCT06076642 -
A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases
|
Phase 3 | |
| Completed |
NCT00782106 -
Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously
|
Phase 1/Phase 2 | |
| Completed |
NCT01485796 -
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
|
Phase 2/Phase 3 | |
| Recruiting |
NCT06150534 -
At-Home Subcutaneous Immunoglobulin Replacement Therapy Using Alexa Skill
|
||
| Completed |
NCT00814320 -
Gammagard Liquid and rHuPH20 in PID
|
Phase 3 | |
| Completed |
NCT04346108 -
A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID)
|
Phase 3 |